

# Ernst K Schonbrunn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4114268/publications.pdf>

Version: 2024-02-01

37  
papers

1,593  
citations

393982

19  
h-index

329751

37  
g-index

38  
all docs

38  
docs citations

38  
times ranked

2687  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Discovery of Dual TAF1-ATR Inhibitors and Ligand-Induced Structural Changes of the TAF1 Tandem Bromodomain. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 4182-4200.   | 2.9 | 10        |
| 2  | Dihydropyridine Lactam Analogs Targeting BET Bromodomains. <i>ChemMedChem</i> , 2022, 17, e202100407.  | 1.6 | 1         |
| 3  | Tetrahydroindazole inhibitors of CDK2/cyclin complexes. <i>European Journal of Medicinal Chemistry</i> , 2021, 214, 113232.  | 2.6 | 5         |
| 4  | Development of Dimethylisoxazole-Attached Imidazo[1,2- <i>a</i> ]pyridines as Potent and Selective CBP/P300 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5787-5801.                               | 2.9 | 15        |
| 5  | New Design Rules for Developing Potent Cell-Active Inhibitors of the Nucleosome Remodeling Factor (NURF) via BPTF Bromodomain Inhibition. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 13902-13917.           | 2.9 | 14        |
| 6  | Synthesis and structural characterization of a monocarboxylic inhibitor for GRB2 SH2 domain. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 51, 128354.   | 1.0 | 5         |
| 7  | Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 2228-2241.   | 2.9 | 49        |
| 8  | Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 15772-15786.  | 2.9 | 10        |
| 9  | NMR Analyses of Acetylated H2A.Z Isoforms Identify Differential Binding Interactions with the Bromodomain of the NURF Nucleosome Remodeling Complex. <i>Biochemistry</i> , 2020, 59, 1871-1880.                    | 1.2 | 11        |
| 10 | New inhibitors for the BPTF bromodomain enabled by structural biology and biophysical assay development. <i>Organic and Biomolecular Chemistry</i> , 2020, 18, 5174-5182.  | 1.5 | 14        |
| 11 | Development of WEE2 kinase inhibitors as novel non-hormonal female contraceptives that target meiosis. <i>Biology of Reproduction</i> , 2020, 103, 368-377.  | 1.2 | 7         |
| 12 | Structural Basis of Inhibitor Selectivity in the BRD7/9 Subfamily of Bromodomains. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 3227-3237.  | 2.9 | 19        |
| 13 | Identification and Screening of Selective WEE2 Inhibitors to Develop Non-Hormonal Contraceptives that Specifically Target Meiosis. <i>ChemistrySelect</i> , 2019, 4, 13363-13369.                                  | 0.7 | 7         |
| 14 | Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon. <i>Journal of Biological Chemistry</i> , 2018, 293, 6187-6200. | 1.6 | 32        |
| 15 | Structural Basis of ALDH1A2 Inhibition by Irreversible and Reversible Small Molecule Inhibitors. <i>ACS Chemical Biology</i> , 2018, 13, 582-590.  | 1.6 | 48        |
| 16 | Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 9316-9334.                          | 2.9 | 56        |
| 17 | Design, Synthesis, and Characterization of a Fluorescence Polarization Pan-BET Bromodomain Probe. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 1223-1229.   | 1.3 | 8         |
| 18 | BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4805-4817.  | 2.9 | 39        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity. ACS Chemical Biology, 2017, 12, 1883-1892.   | 1.6 | 57        |
| 20 | Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics. Molecular Cancer Therapeutics, 2017, 16, 1054-1067.  | 1.9 | 40        |
| 21 | Structure-Activity Studies of <i>N</i> -Butyl- $\epsilon$ -deoxynojirimycin ( <i>N</i> -BDNJ) Analogues: Discovery of Potent and Selective Aminocyclopentitol Inhibitors of GBA1 and GBA2. ChemMedChem, 2017, 12, 1977-1984.                               | 1.6 | 13        |
| 22 | Advances of small molecule targeting of kinases. Current Opinion in Chemical Biology, 2017, 39, 126-132.   | 2.8 | 44        |
| 23 | Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 7863-7875.  | 2.9 | 68        |
| 24 | Discovery of Diverse Small-Molecule Inhibitors of Mammalian Sterile- $\alpha$ -like Kinase-3 (MST3). ChemMedChem, 2016, 11, 1137-1144.   | 1.6 | 22        |
| 25 | An Advanced Tool To Interrogate BRD9. Journal of Medicinal Chemistry, 2016, 59, 4459-4461.   | 2.9 | 13        |
| 26 | Stability of the Human Hsp90-p50Cdc37 Chaperone Complex against Nucleotides and Hsp90 Inhibitors, and the Influence of Phosphorylation by Casein Kinase 2. Molecules, 2015, 20, 1643-1660.   | 1.7 | 12        |
| 27 | Fluorinated Aromatic Amino Acids Are Sensitive $^{19}\text{F}$ NMR Probes for Bromodomain-Ligand Interactions. ACS Chemical Biology, 2014, 9, 2755-2760.   | 1.6 | 79        |
| 28 | Differential antibacterial properties of the MurA inhibitors terreic acid and fosfomycin. Journal of Basic Microbiology, 2014, 54, 322-326.  | 1.8 | 22        |
| 29 | Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors. ACS Chemical Biology, 2014, 9, 1160-1171.  | 1.6 | 188       |
| 30 | Development of Highly Potent and Selective Diaminotiazole Inhibitors of Cyclin-Dependent Kinases. Journal of Medicinal Chemistry, 2013, 56, 3768-3782.   | 2.9 | 73        |
| 31 | Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains. ACS Chemical Biology, 2013, 8, 2360-2365.  | 1.6 | 132       |
| 32 | Synthesis and Evaluation of Eight- and Four-Membered Iminosugar Analogues as Inhibitors of Testicular Ceramide-Specific Glucosyltransferase, Testicular $\beta$ -Glucosidase 2, and Other Glycosidases. Journal of Organic Chemistry, 2012, 77, 3082-3098. | 1.7 | 38        |
| 33 | A Novel Approach to the Discovery of Small-Molecule Ligands of CDK2. ChemBioChem, 2012, 13, 2128-2136.   | 1.3 | 65        |
| 34 | A Novel Mechanism by Which Small Molecule Inhibitors Induce the DFG Flip in Aurora A. ACS Chemical Biology, 2012, 7, 698-706.  | 1.6 | 58        |
| 35 | Discovery of a Potential Allosteric Ligand Binding Site in CDK2. ACS Chemical Biology, 2011, 6, 492-501.   | 1.6 | 151       |
| 36 | The Fungal Product Terreic Acid Is a Covalent Inhibitor of the Bacterial Cell Wall Biosynthetic Enzyme UDP- <i>N</i> -Acetylglucosamine 1-Carboxyvinyltransferase (MurA). Biochemistry, 2010, 49, 4276-4282.   | 1.2 | 50        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Evidence That the Fosfomycin Target Cys115 in UDP-N-acetylglucosamine Enolpyruvyl Transferase (MurA) Is Essential for Product Release. Journal of Biological Chemistry, 2005, 280, 3757-3763. | 1.6 | 117       |